Clinical Trials
3
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
Phase 1
Recruiting
- Conditions
- CNS LymphomaPrimary Central Nervous System LymphomaSecondary Central Nervous System Lymphoma
- Interventions
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- James Rubenstein
- Target Recruit Count
- 35
- Registration Number
- NCT05351593
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma
Phase 1
Recruiting
- Conditions
- Primary CNS Lymphoma
- Interventions
- Procedure: Magnetic resonance imaging (MRI)
- First Posted Date
- 2020-12-07
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- James Rubenstein
- Target Recruit Count
- 25
- Registration Number
- NCT04656431
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma
Phase 1
Completed
- Conditions
- Recurrent/Refractory CNSIntraocular Lymphoma
- Interventions
- First Posted Date
- 2012-03-02
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- James Rubenstein
- Target Recruit Count
- 14
- Registration Number
- NCT01542918
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
News
No news found